ArticlePloS one2026
The anti-infective potential of human milk oligosaccharides in carbohydrate powder in implant-associated infection with Staphylococcus aureus.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPeriprosthetic joint and implant-associated infections remain serious complications despite highly standardized diagnostic and therapeutic protocols. Repeated revision procedures substantially increase morbidity and the risk of therapeutically uncontrollable infection scenarios. This pilot study, we evaluated the effect of HMO (human milk oligosaccharides)-containing carbohydrates on S. aureus biofilm formation using crystal violet assays and implant models.
methodsS. aureus EDCC 5055 biofilm formation was quantified in the presence of HMO-containing carbohydrates (HMO-C) at concentrations of 5%, 7%, 9%, and 11% and lactose-alone in 96-well plates. After processing, the plate contents were read out using a 595nm Phomo plate reader (Anthos Mikrosystems, Krefeld, Germany). Biofilm activity was further evaluated on titanium disks pre-incubated with HMO-C solutions. Bacterial growth kinetics were also analyzed in TSB with the 5% to 11% HMO-C solutions.
resultsThe results demonstrated a significant reduction in S. aureus biofilm formation with the addition of HMO-C (HMO-C-5%: mean value ([Formula: see text])=0.271nm; p = 0.021; HMO-C groups 7%-11%: [Formula: see text] = 0.211nm, 0.179nm, 0.147nm; All p = 0.001) against the positive control EDCC 5055 (PC) ([Formula: see text] = 0.335nm). Lactose (L) alone did not significantly affect biofilm formation (L5%-11%: p = 1.0). No significant biofilm reduction was observed for titanium implants, though medium changes indicated bacterial inhibition at higher HMO-C solutions (9%-11%: [Formula: see text] = 0.844nm, 0.940nm; Both p = 0.001).
conclusionMedia supplemented with HMOS-C significantly reduced S. aureus ED CC 5055 biofilm formation in vitro in the crystal violet microtiter plate assay. Bacterial invasion on titanium could not be demonstrably changed, but S. aureus growth curve was significantly reduced. Further studies with optimized implant models and standardized HMO formulations are warranted to clarify the translational potential of HMO-C for the prevention of implant-associated infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.